BR112019017417A2 - composições farmacêuticas de um derivado de um ácido biliar e microbioma e usos das mesmas - Google Patents

composições farmacêuticas de um derivado de um ácido biliar e microbioma e usos das mesmas Download PDF

Info

Publication number
BR112019017417A2
BR112019017417A2 BR112019017417A BR112019017417A BR112019017417A2 BR 112019017417 A2 BR112019017417 A2 BR 112019017417A2 BR 112019017417 A BR112019017417 A BR 112019017417A BR 112019017417 A BR112019017417 A BR 112019017417A BR 112019017417 A2 BR112019017417 A2 BR 112019017417A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
microbiome
acid derivative
bile acid
species
Prior art date
Application number
BR112019017417A
Other languages
English (en)
Inventor
Babakhani Farah
D Wu Gary
Lee Hongzhe
Adorini Luciano
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of BR112019017417A2 publication Critical patent/BR112019017417A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a composições farmacêuticas compreendendo um composto de fórmula i e uma ou mais espécies de microbioma intestinal, e a métodos de preparação e uso das mesmas.
BR112019017417A 2017-02-23 2018-02-23 composições farmacêuticas de um derivado de um ácido biliar e microbioma e usos das mesmas BR112019017417A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462658P 2017-02-23 2017-02-23
PCT/US2018/019451 WO2018156916A2 (en) 2017-02-23 2018-02-23 Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof

Publications (1)

Publication Number Publication Date
BR112019017417A2 true BR112019017417A2 (pt) 2020-04-07

Family

ID=63254469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019017417A BR112019017417A2 (pt) 2017-02-23 2018-02-23 composições farmacêuticas de um derivado de um ácido biliar e microbioma e usos das mesmas

Country Status (12)

Country Link
US (1) US20200164005A1 (pt)
EP (1) EP3585405A4 (pt)
JP (1) JP2020509001A (pt)
KR (1) KR20190117687A (pt)
CN (1) CN110461337A (pt)
AU (1) AU2018225255A1 (pt)
BR (1) BR112019017417A2 (pt)
CA (1) CA3053935A1 (pt)
IL (1) IL268760A (pt)
MX (1) MX2019009861A (pt)
SG (1) SG11201907742YA (pt)
WO (1) WO2018156916A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735224A4 (en) * 2018-01-05 2021-11-03 Nubyiota LLC COMPOSITIONS CONSISTING OF A CO-SELECTED MICROBIOTE AND METHODS OF USE OF THE LATTER
EP3785269A4 (en) * 2018-03-29 2021-12-29 Freenome Holdings, Inc. Methods and systems for analyzing microbiota
ES2763350B2 (es) * 2018-11-28 2020-10-13 Consejo Superior Investigacion Cepa de christensenella minuta y uso de la misma
US11980645B2 (en) * 2019-01-22 2024-05-14 The Regents Of The University Of California Bile acids and use in disease treatment
AU2020218984A1 (en) * 2019-02-04 2021-08-12 Keio University Pharmaceutical composition for preventing, ameliorating or treating skin disease
WO2020163201A1 (en) * 2019-02-04 2020-08-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
WO2020198503A1 (en) * 2019-03-26 2020-10-01 The Children's Medical Center Corporation Therapeutic microbiota for the treatment and/or prevention of dysbiosis
CN109852604A (zh) * 2019-03-28 2019-06-07 贵州大学 高效降解菌核净的单胞属菌固定化菌的制备方法及应用
KR102395036B1 (ko) * 2019-07-30 2022-05-09 주식회사 고바이오랩 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 진단방법
CN112980712A (zh) * 2019-12-14 2021-06-18 山东大学 一种调节高原人群情绪及肠道菌群稳定的微生物组合物及其应用
WO2021137494A1 (ko) * 2020-01-02 2021-07-08 삼육대학교산학협력단 부티리시모나스 속 균주를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물
CN113213984B (zh) * 2020-01-21 2022-09-09 吉林农业大学 一种含死谷芽孢杆菌的生物有机肥及其制备方法和应用
CN111254207A (zh) * 2020-01-22 2020-06-09 郑州大学第一附属医院 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用
CN111117935A (zh) * 2020-02-10 2020-05-08 农业农村部食物与营养发展研究所 一种抑制肌肉合成的微生物菌剂及其应用
CA3175041A1 (en) * 2020-03-10 2021-09-16 Federation Bio Inc. Microbial consortia for the treatment of disease
CN111686134A (zh) * 2020-05-15 2020-09-22 上海市第六人民医院东院 一种益生菌组合物及其制备方法和用途
US20230233620A1 (en) * 2020-05-21 2023-07-27 Chan Zuckerberg Biohub, Inc. High-complexity synthetic gut bacterial communities
EP4188110A4 (en) * 2020-07-30 2024-08-14 Bactana Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC CONDITIONS
KR102269966B1 (ko) 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113186132B (zh) * 2021-05-07 2023-05-23 广东丽豪生物农业有限公司 一种适于玉米种植的微生物菌剂和应用
US20240277781A1 (en) * 2021-06-21 2024-08-22 Pendulum Therapeutics, Inc. Compositions Comprising Microbes and Methods of Use and Making Thereof
CN114028938B (zh) * 2021-10-13 2024-03-22 华中农业大学 一株耐高温除氨菌的筛选及应用
CN113789289B (zh) * 2021-11-05 2023-05-16 中山大学附属第三医院粤东医院 评估系统性红斑狼疮患病风险的肠道微生物组合及其检测试剂
CN113881609B (zh) * 2021-11-23 2022-12-23 山东省花生研究所 一株皮特不动杆菌yy-7s及其应用
CN114410554B (zh) * 2022-03-29 2022-06-14 广东省科学院生态环境与土壤研究所 一株具有好氧砷甲基化和挥发功能的噬几丁质菌及其应用
TW202408498A (zh) * 2022-06-30 2024-03-01 南韓商日東製藥股份有限公司 異噁唑衍生物及其鹽之新用途
CN115161406B (zh) * 2022-07-18 2023-04-21 中国农业科学院特产研究所 一种合成菌群的构建方法及其在药用植物高品质栽培中的应用
CN115232772B (zh) * 2022-08-04 2024-05-14 湖北稻花香酒业股份有限公司 Rf1菌及联合科氏梭菌产己酸的方法
WO2024102925A1 (en) * 2022-11-11 2024-05-16 Intercept Pharmaceuticals, Inc. Crystalline forms of a farnesoid x receptor agonist
CN115747111B (zh) * 2022-11-25 2023-12-12 四川大学 一株戊糖片球菌及其应用
CN115976122B (zh) * 2023-01-10 2024-07-23 四川轻化工大学 一种二元混菌产酯发酵体系及其生产酯化液的方法和应用
CN116694535B (zh) * 2023-07-20 2024-08-23 四川大学 一种戊糖乳杆菌w19及其应用
CN117797176B (zh) * 2024-03-01 2024-07-02 南京大学 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014267324B2 (en) * 2013-05-14 2017-11-02 Intercept Pharmaceuticals, Inc. 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid X receptor modulators
US20150258052A1 (en) * 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
US20160095339A1 (en) * 2014-10-01 2016-04-07 Mead Johnson Nutrition Company Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
CN106083978A (zh) * 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
CN110461337A (zh) 2019-11-15
SG11201907742YA (en) 2019-09-27
CA3053935A1 (en) 2018-08-30
MX2019009861A (es) 2020-07-14
US20200164005A1 (en) 2020-05-28
EP3585405A2 (en) 2020-01-01
JP2020509001A (ja) 2020-03-26
IL268760A (en) 2019-10-31
AU2018225255A1 (en) 2019-09-05
KR20190117687A (ko) 2019-10-16
WO2018156916A3 (en) 2018-10-11
EP3585405A4 (en) 2020-12-09
WO2018156916A2 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
BR112019017417A2 (pt) composições farmacêuticas de um derivado de um ácido biliar e microbioma e usos das mesmas
CO2021005987A2 (es) Compuestos de anillo fusionado
BR112017005393A2 (pt) composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
EA201691978A1 (ru) Соединения в качестве модуляторов ror гамма
BR112019024747A2 (pt) formulações de dose fixa
PH12019501359A1 (en) Polymorphs
EA201691141A1 (ru) Соединения против ccr6
CY1123574T1 (el) Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
PH12019501362A1 (en) Polymorphs
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201790570A1 (ru) Модуляторы р2х7
EA201892514A1 (ru) Промежуточные соединения для синтеза производных желчных кислот, в частности обетихолевой кислоты
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
MX2020006016A (es) Polimorfos.
BR112022012737A2 (pt) Composto antagonista de pd-l1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]